15850-29-0

Usage

Uses

Used in Pharmaceutical Research and Development:
4-(4-Ethoxy-phenyl)-thiazol-2-ylamine is used as a key intermediate in the synthesis of various drugs and biologically active compounds, contributing to the advancement of novel therapeutic agents.
Used in Cancer Treatment:
In the field of oncology, 4-(4-ethoxy-phenyl)-thiazol-2-ylamine is used as a potential therapeutic agent for the treatment of various types of cancer, due to its ability to target and inhibit the growth of cancer cells.
Used in Inflammatory Disorder Treatment:
4-(4-Ethoxy-phenyl)-thiazol-2-ylamine is utilized as a potential treatment for inflammatory disorders, leveraging its capacity to modulate immune responses and reduce inflammation.
Used in Antimicrobial Applications:
In the medical and agricultural sectors, 4-(4-ethoxy-phenyl)-thiazol-2-ylamine is used as an antimicrobial agent to combat bacterial infections, highlighting its broad-spectrum activity against various pathogens.
Used in Antifungal Applications:
Similarly, 4-(4-ethoxy-phenyl)-thiazol-2-ylamine is employed as an antifungal agent, effective against a range of fungal species, which is crucial for treating fungal infections and controlling fungal growth in agricultural settings.

InChI:InChI=1/C11H12N2OS/c1-2-14-9-5-3-8(4-6-9)10-7-15-11(12)13-10/h3-7H,2H2,1H3,(H2,12,13)

Upstream product

• 17356-08-0 thiourea 
• 1676-63-7 4'-ethoxyacetophenone 
• 99-93-4 4-Hydroxyacetophenone 
• 51012-63-6 2-bromo-4'-ethoxyacetophenone 

Downstream Products

• 398-25-4 4-fluoro-benzenesulfonic acid-[4-(4-ethoxy-phenyl)-thiazol-2-ylamide] 
• 115035-26-2 4,4'-bis-(4-ethoxy-phenyl)-5,5'-benzylidene-bis-thiazol-2-ylamine 
• 69396-09-4 N-{[4-(4-ethoxy-phenyl)-thiazol-2-ylamino]-methyl}-phthalimide 
• 50891-62-8 3-(4-ethoxy-phenyl)-6,8-dimethyl-7-nitro-pyrido[2,3-d]thiazolo[3,2-a]pyrimidin-5-ylideneamine 
• 56921-58-5 3-(4-ethoxy-phenyl)-6-p-tolyl-imidazo[2,1-b]thiazole 
• 56921-57-4 3-(4-ethoxy-phenyl)-6-(4-methoxy-phenyl)-imidazo[2,1-b]thiazole 
• 77203-60-2 2,4-Dibromo-6-{[(E)-4-(4-ethoxy-phenyl)-thiazol-2-ylimino]-methyl}-phenol 
• 113688-74-7 2-{[(E)-4-(4-Ethoxy-phenyl)-thiazol-2-ylimino]-methyl}-4-methyl-phenol 
• 97855-12-4 4-[2-Amino-4-(4-ethoxy-phenyl)-thiazol-5-ylazo]-N-thiazol-2-yl-benzenesulfonamide 
• 97854-84-7 4-[2-Amino-4-(4-ethoxy-phenyl)-thiazol-5-ylazo]-N-pyrimidin-2-yl-benzenesulfonamide 
• 97854-90-5 4-[2-Amino-4-(4-ethoxy-phenyl)-thiazol-5-ylazo]-N-(2-methyl-pyrimidin-4-yl)-benzenesulfonamide 
• 97855-07-7 4-[2-Amino-4-(4-ethoxy-phenyl)-thiazol-5-ylazo]-N-(4,6-dimethyl-pyrimidin-2-yl)-benzenesulfonamide 
• 97855-23-7 4-[2-Amino-4-(4-ethoxy-phenyl)-thiazol-5-ylazo]-N-(3,4-dimethyl-isoxazol-5-yl)-benzenesulfonamide 
• 97855-02-2 4-[2-Amino-4-(4-ethoxy-phenyl)-thiazol-5-ylazo]-N-(6-methoxy-pyridazin-3-yl)-benzenesulfonamide 

Relevant academic research and scientific papers

Synthesis of 2-aminothiazole derivatives from easily available thiourea and alkyl/aryl ketones using aqueous NaICl2

A simple methodology was developed to synthesize substituted aminothiazoles from the corresponding thiourea and substituted ketones using aqueous NaICl2 at reflux temperature in THF. The products were obtained in good to excellent yields.

Development of 2-amino-4-phenylthiazole analogues to disrupt myeloid differentiation factor 88 and prevent inflammatory responses in acute lung injury

Myeloid differentiation primary response protein 88 (MyD88), an essential adapter protein used by toll-like receptors (TLR), is a promising target molecule for the treatment of respiratory inflammatory diseases. Previous studies explored the activities of novel 2-amino-4-phenylthiazole analogue (6) in inflammation-induced cancer, and identified the analogue as an inhibitor of MyD88 toll/interleukin-1 receptor (TIR) homology domain dimerization. Here, we describe the synthesis of 47 new analogues by modifying different sites on this lead compound and assessed their anti-inflammatory activities in lipopolysaccharide-induced mouse primary peritoneal macrophages (MPMs). The most promising compound, 15d, was found to effectively interact with MyD88 protein and prevented formation of the MyD88 homodimeric complex. Furthermore, 15d showed in vivo anti-inflammatory activity in LPS-caused model of acute lung injury. This work provides new candidates as MyD88 inhibitors to combat inflammation diseases.

NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

Disclosed are compounds of formula (I) below and pharmaceutically acceptable salts thereof: Formula (I), in which each of variables L, R3, R4, Y, Z1, Z2 and Z3 is defined herein. Also disclosed is a method for treating a cancer with a compound of formula (I) or a salt thereof and a pharmaceutical composition containing same.